Sanofi Stock Prediction and Forecast [SNY]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 25 Nov 2025, 04:42 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Sanofi Stock Prediction and Forecast [SNY]](https://i.ytimg.com/vi/nFSCR6VpUGA/hqdefault.jpg)
AI-generated source summary
Sanofi (SNY) shows a negative trend with mixed headlines. Recent analyst ratings are predominantly sell/hold, with a few buy signals. While some short-term and long-term technical indicators suggest a bearish outlook with expected resistance at $50.26 and $50.10, there's a positive overall trend observed in the past three months. However, the stock's recent performance, including a drop of -6.09% from a pivot top, and a sustained decline in volume alongside price movement, indicates a sell signal. The stock is currently trading below its 50-day and 200-day moving averages, reinforcing the bearish sentiment. Despite a positive outlook on a new drug indication, the stock is facing legal and reputational risks. The price is currently testing support at $45.65, and a break below this level could lead to further declines. The P/E ratio of 11.54 suggests the stock might be undervalued, but the negative signals and recent price action point towards a short-term bearish outlook.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.